This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Press Releases

Newly-Formed European Thrombosis & Haemostasis Alliance Calls for Patient Safety & Research Strategy

Tuesday, March 27, 2018   (0 Comments)
Posted by: Barbara Krolak
Share |

BRUSSELS – 27 March 2018 – The European Thrombosis and Haemostasis Alliance (ETHA) has been recently formed to advocate for better awareness and prioritisation of thrombosis and haemostasis in European Union (EU) patient safety and research programmes. ETHA, with its 21 national thrombosis and haemostasis society members, has a united focus on better addressing thrombosis, also known as clotting, and improving the understanding of haemostasis. ETHA stands to work with the public and decision-makers to share expertise in clotting and bleeding disorders, elevate patient-centric policies and promote improved outcomes in the EU. 

As an initial area of priority, ETHA is highlighting the urgent need to better understand the condition of thrombosis. One in four people worldwide die of conditions caused by blood clots, also known by the clinical term thrombosis.[i] Thrombosis is the underlying cause of many cardiovascular disorders including heart attack, thromboembolic stroke and venous thromboembolism (VTE). VTE is a significant international patient safety issue and the number one cause of preventable hospital mortality. There are approximately 544,000 VTE deaths in Europe each year[ii]. To reduce harm from this common disorder, ETHA calls on decision-makers to take note of the risk of VTE and mandate VTE risk assessment for all hospital patients in the EU.

Dr. Anna Falanga, Chair of ETHA said, “For too long the burden of thrombosis has been under-recognized. Every European could be affected, whether they are young or old, sick or well, man or woman. The EU can make a real difference in this area, by reaffirming and strengthening its commitment to research into thrombosis and haemostasis through its upcoming Framework 9 funding package, which will support the long-term sustainability of European health systems.”

To elevate this critical health priority, ETHA will hold a panel discussion event on 3 May in the European Parliament hosted by MEP Aldo Patriciello (EPP, Italy).  The event will discuss the burden of thrombosis in the EU and the need for the EU to adopt an ambitious Framework Programme 9 in the field of health to enable sustainable health systems through greater understanding, diagnosis and treatment of blood and clotting disorders.

About the ETHA

Initiated by the International Society on Thrombosis and Haemostasis (ISTH), the European Thrombosis and Haemostasis Alliance (ETHA) is made up of European national societies representing those working in the field of thrombotic and bleeding disorders. ETHA has come together to give the European thrombosis and haemostasis community an allied voice and provide input to EU health and patient safety strategies; make recommendations on EU research programme funding and encourage sharing and adoption of best practices in the treatment and prevention of thrombotic and bleeding disorders across Member States. For a full list of member organizations and to learn more about the alliance, visit

Media Contact

For media inquiries, please contact or Sture Alne on +32 488568225.

[i] World Thrombosis Day. Know Thrombosis. Available at:

[ii] Cohen AT, Agnelli G, Anderson FA et al. “Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.” J Thromb Haemost, 2007;98:756–764

Membership Management Software Powered by YourMembership  ::  Legal